Is Crescent Biopharma, Inc. (CBIO) a Buy, Sell, or Hold?
Crescent Biopharma, Inc.
NASDAQ:CBIO
$15.305 USD
-$0.39 (-2.45%)
- Volume
- 77.93K
- Average Volume
- 319.62K
- Market Capitalization
- $421.99M
- P/E Ratio
- -1.40
- Dividend Yield
- 0.00%
- Price Target
- $35.00
- Year High
- $27.41
- Year Low
- $8.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $13.78
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
39
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
7
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$ 68156
CBIO Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
CBIO Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Lynch Ryan | officer: See Remarks | 2026-06-22 | S-Sale | 17.99 | 2026-06-23 |
| Pinkas Jan | officer: Chief Scientific Officer | 2026-06-22 | S-Sale | 17.99 | 2026-06-23 |
| Scalzo Richard William | officer: Chief Financial Officer | 2026-06-22 | S-Sale | 17.99 | 2026-06-23 |
| Bispham Barbara Harlin | officer: See Remarks | 2026-06-22 | S-Sale | 17.99 | 2026-06-23 |
| Im Ellie Eunkyung | officer: Chief Medical Officer | 2026-06-22 | S-Sale | 17.99 | 2026-06-23 |
| McNeill Jonathan | officer: President and COO | 2026-06-22 | S-Sale | 17.99 | 2026-06-23 |
| Brumm Joshua T | director, officer: Chief Executive Officer | 2026-06-22 | S-Sale | 17.99 | 2026-06-23 |
| Violin Jonathan | director | 2026-06-02 | A-Award | 17.01 | 2026-06-03 |
| Lubner David Charles | director | 2026-06-02 | A-Award | 17.01 | 2026-06-03 |
| Balcom Alexandra | director | 2026-06-02 | A-Award | 17.01 | 2026-06-03 |
| Moran Susan | director | 2026-06-02 | A-Award | 17.01 | 2026-06-03 |
| Fairmount Funds Management LLC | director, 10 percent owner: | 2026-06-02 | A-Award | 17.01 | 2026-06-03 |
| Pinkas Jan | officer: Chief Scientific Officer | 2025-12-15 | A-Award | 13.21 | 2025-12-17 |
| Pinkas Jan | officer: Chief Scientific Officer | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Pinkas Jan | officer: Chief Scientific Officer | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Doughty Christopher Grant | officer: Chief Business Officer | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Doughty Christopher Grant | officer: Chief Business Officer | 2025-12-15 | A-Award | 13.21 | 2025-12-17 |
| Doughty Christopher Grant | officer: Chief Business Officer | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Brumm Joshua T | director, officer: Chief Executive Officer | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Brumm Joshua T | director, officer: Chief Executive Officer | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Brumm Joshua T | director, officer: Chief Executive Officer | 2025-12-15 | A-Award | 13.21 | 2025-12-17 |
| Scalzo Richard William | officer: Chief Financial Officer | 2025-12-15 | A-Award | 13.21 | 2025-12-17 |
| Scalzo Richard William | officer: Chief Financial Officer | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Scalzo Richard William | officer: Chief Financial Officer | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| McNeill Jonathan | officer: President and COO | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| McNeill Jonathan | officer: President and COO | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| McNeill Jonathan | officer: President and COO | 2025-12-15 | A-Award | 13.21 | 2025-12-17 |
| Im Ellie Eunkyung | officer: Chief Medical Officer | 2025-12-15 | A-Award | 13.21 | 2025-12-17 |
| Im Ellie Eunkyung | officer: Chief Medical Officer | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Im Ellie Eunkyung | officer: Chief Medical Officer | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Lynch Ryan | officer: See Remarks | 2025-12-15 | A-Award | 13.21 | 2025-12-17 |
| Lynch Ryan | officer: See Remarks | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Lynch Ryan | officer: See Remarks | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Bispham Barbara Harlin | officer: See Remarks | 2025-12-15 | A-Award | 13.21 | 2025-12-17 |
| Bispham Barbara Harlin | officer: See Remarks | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| Bispham Barbara Harlin | officer: See Remarks | 2025-12-15 | A-Award | 0 | 2025-12-17 |
| McNeill Jonathan | officer: President and COO | 2025-12-08 | A-Award | 13.17 | 2025-12-10 |
| Brumm Joshua T | director, officer: Chief Executive Officer | 2025-12-08 | A-Award | 13.17 | 2025-12-10 |
| Fairmount Funds Management LLC | director, 10 percent owner: | 2025-12-04 | P-Purchase | 13.41 | 2025-12-08 |
| Fairmount Funds Management LLC | director, 10 percent owner: | 2025-12-04 | P-Purchase | 0.001 | 2025-12-08 |
| Pinkas Jan | officer: Chief Scientific Officer | 2025-07-16 | A-Award | 13.14 | 2025-07-16 |
| Pinkas Jan | officer | 2025-07-07 | 0 | 2025-07-15 | |
| Moran Susan | director | 2025-06-23 | A-Award | 15.3 | 2025-06-23 |
| Fairmount Funds Management LLC | director, 10 percent owner: | 2025-06-23 | A-Award | 15.3 | 2025-06-23 |
| Violin Jonathan | director | 2025-06-23 | A-Award | 15.3 | 2025-06-23 |
| Balcom Alexandra | director | 2025-06-23 | A-Award | 15.3 | 2025-06-23 |
| Lubner David Charles | director | 2025-06-23 | A-Award | 15.3 | 2025-06-23 |
| Invus Public Equities, L.P. | 10 percent owner | 2024-08-07 | S-Sale | 0.1821 | 2024-08-09 |
| Invus Public Equities, L.P. | 10 percent owner | 2024-08-08 | S-Sale | 0.1917 | 2024-08-09 |
| Invus Public Equities, L.P. | 10 percent owner | 2024-08-05 | S-Sale | 0.1884 | 2024-08-07 |
| Invus Public Equities, L.P. | 10 percent owner | 2024-08-06 | S-Sale | 0.1828 | 2024-08-07 |
| Invus Public Equities, L.P. | 10 percent owner | 2024-08-01 | S-Sale | 0.2162 | 2024-08-05 |
| Invus Public Equities, L.P. | 10 percent owner | 2024-08-02 | S-Sale | 0.2004 | 2024-08-05 |
| Invus Public Equities, L.P. | 10 percent owner | 2024-07-26 | S-Sale | 0.2417 | 2024-07-30 |
| Invus Public Equities, L.P. | 10 percent owner | 2024-07-29 | S-Sale | 0.2353 | 2024-07-30 |
| Invus Public Equities, L.P. | 10 percent owner | 2024-07-30 | S-Sale | 0.2209 | 2024-07-30 |
| Siren, L.L.C. | 10 percent owner | 2024-07-25 | 0 | 2024-07-29 | |
| Rock Edwin | officer: Chief Medical Officer | 2024-06-21 | P-Purchase | 0.2671 | 2024-06-24 |
| Rock Edwin | officer: Chief Medical Officer | 2024-06-20 | P-Purchase | 0.2532 | 2024-06-24 |
| Hahn Brian M. | officer: SVP Finance, CFO | 2024-06-18 | P-Purchase | 0.2477 | 2024-06-20 |
| Koenig Scott | director | 2024-05-01 | A-Award | 1.62 | 2024-05-01 |
| Goldberg Mark Alan | director | 2024-05-01 | A-Award | 1.62 | 2024-05-01 |
| PEARSON TIMOTHY R | director | 2024-05-01 | A-Award | 1.62 | 2024-05-01 |
| King Rachel K. | director | 2024-05-01 | A-Award | 1.62 | 2024-05-01 |
| Andrews Patricia S | director | 2024-05-01 | A-Award | 1.62 | 2024-05-01 |
| Jackson Scott Thomas | director | 2024-05-01 | A-Award | 1.62 | 2024-05-01 |
| JUNIUS DANIEL M | director | 2024-05-01 | A-Award | 1.62 | 2024-05-01 |
| JUNIUS DANIEL M | director | 2024-03-29 | A-Award | 3 | 2024-04-02 |
| King Rachel K. | director | 2024-03-29 | A-Award | 3 | 2024-04-02 |
| Goldberg Mark Alan | director | 2024-03-29 | A-Award | 3 | 2024-04-02 |
| Johnson Bruce S | officer: SVP & Chief Commercial Officer | 2024-01-12 | A-Award | 3.11 | 2024-01-17 |
| Semerjian Harout | director, officer: Chief Executive Officer | 2024-01-12 | A-Award | 3.11 | 2024-01-17 |
| Rock Edwin | officer: Chief Medical Officer | 2024-01-12 | A-Award | 3.11 | 2024-01-17 |
| Rath Chinmaya | officer: SVP and Chief Business Officer | 2024-01-12 | A-Award | 3.11 | 2024-01-17 |
| Hahn Brian M. | officer: SVP Finance, CFO | 2024-01-12 | A-Award | 3.11 | 2024-01-17 |
| Andrews Patricia S | director | 2023-12-29 | A-Award | 2.36 | 2024-01-02 |
| King Rachel K. | director | 2023-12-29 | A-Award | 2.36 | 2024-01-02 |
| Goldberg Mark Alan | director | 2023-12-29 | A-Award | 2.36 | 2024-01-02 |
| Goldberg Mark Alan | director | 2023-09-30 | A-Award | 1.5 | 2023-10-03 |
| Andrews Patricia S | director | 2023-09-30 | A-Award | 1.5 | 2023-10-03 |
| King Rachel K. | director | 2023-09-30 | A-Award | 1.5 | 2023-10-03 |
| Rock Edwin | officer: Chief Medical Officer | 2023-09-22 | P-Purchase | 1.38 | 2023-09-25 |
| Rock Edwin | officer: Chief Medical Officer | 2023-09-21 | P-Purchase | 1.38 | 2023-09-25 |
| Koenig Scott | director | 2023-06-01 | M-Exempt | 0.6 | 2023-06-02 |
| Koenig Scott | director | 2023-06-01 | M-Exempt | 0.6 | 2023-06-02 |
| King Rachel K. | director | 2023-05-19 | A-Award | 1.98 | 2023-05-22 |
| JUNIUS DANIEL M | director | 2023-05-19 | A-Award | 1.98 | 2023-05-22 |
| Koenig Scott | director | 2023-05-19 | A-Award | 1.98 | 2023-05-22 |
| Goldberg Mark Alan | director | 2023-05-19 | A-Award | 1.98 | 2023-05-22 |
| PEARSON TIMOTHY R | director | 2023-05-19 | A-Award | 1.98 | 2023-05-22 |
| Andrews Patricia S | director | 2023-05-19 | A-Award | 1.98 | 2023-05-22 |
| Jackson Scott Thomas | director | 2023-05-19 | A-Award | 1.98 | 2023-05-22 |
| Hahn Brian M. | officer: SVP Finance, CFO | 2023-05-17 | S-Sale | 1.95 | 2023-05-18 |
| JUNIUS DANIEL M | director | 2023-05-10 | P-Purchase | 1.56 | 2023-05-11 |
| Johnson Bruce S | officer: SVP & Chief Commercial Officer | 2023-05-08 | P-Purchase | 1.57 | 2023-05-09 |
| Rath Chinmaya | officer: SVP and Chief Business Officer | 2023-03-23 | 0 | 2023-03-31 | |
| Rath Chinmaya | officer: SVP and Chief Business Officer | 2023-03-23 | 3.48 | 2023-03-31 | |
| Johnson Bruce S | officer: SVP & Chief Commercial Officer | 2023-03-23 | 0 | 2023-03-31 | |
| Johnson Bruce S | officer: SVP & Chief Commercial Officer | 2023-03-23 | 1.07 | 2023-03-31 | |
| Johnson Bruce S | officer: SVP & Chief Commercial Officer | 2023-03-23 | 2.55 | 2023-03-31 |